OnKure Therapeutics closed at $2.59 on Nov 4, up 3.60%, 50.9% below its 52-week closing high. Volume of 877.1K shares was 2.64× its 20-day average (well above normal).
Split-adjusted performance: +5.3% over one month, -36.4% over six months, -20.8% over one year.
Short interest was 1.4M shares at the Oct 15 settlement, up 13.2% from the prior report (5.6% of float, 2.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| OKUROnKure Therapeutics | $2.59 | +3.60% | −36.4% | — | — | — | $104.9M | |
| UNCYUnicycive Therapeutics | $3.75 | +4.46% | −53.9% | — | — | — | $104.5M | Compare |
| NRXPNRX Pharmaceuticals | $2.49 | +11.16% | −18.4% | — | −1500.5% | — | $107.8M | Compare |
| IMUXImmunic | $7.94 | +4.47% | −27.9% | — | — | — | $108.3M | Compare |
| HURATuHURA Biosciences | $1.72 | +3.93% | −32.3% | — | — | — | $109.6M | Compare |
| EQEquillium | $1.40 | −0.71% | −35.5% | — | — | — | $109.7M | Compare |
| CATXPerspective Therapeutics | $0.8702 | −1.11% | −77.2% | −72.1% | −33069.1% | — | $99.3M | Compare |
| ORGOOrganogenesis Holdings | $0.8700 | +4.19% | −66.0% | −56.7% | −227.0% | — | $111.9M | Compare |
| ANIXAnixa Biosciences | $3.28 | +7.37% | +7.2% | — | — | — | $114.0M | Compare |
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
